This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy. X

Select your Country and Language

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.

Introducing the Oncotype DX® Test

The Oncotype DX® Breast Cancer test is a multigene diagnostic test that determines the individual risk of cancer recurrence in early-stage invasive breast cancer and identifies patients with minimal, if any, likelihood of benefit, and patients with substantial likelihood of benefit from chemotherapy. The Oncotype DX® test reveals the underlying tumour biology to help guide treatment decisions.

What is the Test?

Onoctype DX 

The Oncotype DX® test analyses the activity of 21 genes from the breast cancer tumour to provide an individual Recurrence Score® result, which is unique to the biology of a patient’s cancer.

Getting Tested

Get Tested 

The Oncotype DX® test should be used when the benefit of chemotherapy for a patient is uncertain. The test increases both the patient and her doctor’s confidence in treatment decisions.

Resources

 

Visit these pages for further information on the Oncotype DX® test, cancer-related terminology, and FAQs.